HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.

Abstract
The novel antimigraine drug 311C90 (Zomig; zolmitriptan) has a high selectivity for serotonin (5HT)1 receptors, mainly 5HT1B and 5HT1D subtypes, and in preclinical studies it has been shown to act on four different sites within the trigemino-vascular system (blockade of neurogenic inflammation by inhibition of peptide release, vasoconstriction, inhibition of neuronal depolarization at peripheral sites, and effects at central sites). Oral 311C90 has a favorable pharmacokinetic profile. It is rapidly absorbed, with 75% of maximal plasma concentration (Cmax) attained within 1 hour and good absolute oral bioavailability (approximately 40%). Clinical studies have shown 311C90 to be rapidly and consistently effective in relieving migraine headache, with initial doses of between 2.5 and 5 mg providing an optimal balance between efficacy and safety considerations. Moreover, the good tolerability of 311C90 is supported by clinical data showing that doses up to 10-fold the therapeutic dose (2.5 mg) did not raise any serious safety concerns, highlighting the favorable safety profile of this drug.
AuthorsM D Ferrari
JournalNeurology (Neurology) Vol. 48 Issue 3 Suppl 3 Pg. S21-4 (Mar 1997) ISSN: 0028-3878 [Print] United States
PMID9071266 (Publication Type: Comparative Study, Journal Article, Review)
Chemical References
  • HTR1B protein, human
  • Oxazoles
  • Oxazolidinones
  • Receptor, Serotonin, 5-HT1B
  • Receptor, Serotonin, 5-HT1D
  • Receptors, Serotonin
  • Serotonin Receptor Agonists
  • Tryptamines
  • zolmitriptan
Topics
  • Headache (drug therapy)
  • Humans
  • Migraine Disorders (drug therapy)
  • Oxazoles (adverse effects, therapeutic use)
  • Oxazolidinones
  • Receptor, Serotonin, 5-HT1B
  • Receptor, Serotonin, 5-HT1D
  • Receptors, Serotonin (physiology)
  • Serotonin Receptor Agonists (adverse effects, therapeutic use)
  • Tryptamines

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: